aap closes Q1 2024 with sales growth of 5.6% and positive developments at
all operating levels and makes a strong start to Q2 2024

EQS-News: aap Implantate AG / Key word(s): Quarter Results/Development of
Sales
aap closes Q1 2024 with sales growth of 5.6% and positive developments at
all operating levels and makes a strong start to Q2 2024

22.04.2024 / 07:30 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

* Sales increase by 5.6% compared to the same quarter of the previous year

* Major order and parts of Q1 sales form strong basis for growth in Q2

  * Human clinical trial of the innovative antibacterial implant technology
    is progressing positively and opens up the possibility of an earlier
    conclusion

aap Implantate AG ("aap" or "Company") continued its good start into the new
year. The regions LATAM and APAC contributed significantly to growth.

Q1/2024 - Sales

    Sales in TEUR                         Q1/2024 Q1/2023 Change
    EMEA (= Europe, Middle East, Africa)    1,456    1,533   -5.0 %
    North America                             731      897  -18.5 %
    LATAM (= Latin America)                   788      481  +63.8 %
    APAC (= Asia-Pacific)                     149       46  >+100 %
    Sales                                   3,124    2,957   +5.6 %

In the EMEA region, aap achieved double-digit growth, particularly in South
Africa (+21% year-on-year), Spain/Portugal (+11% year-on-year) and Germany
(+11% year-on-year). An order placed from the Middle East had to be
postponed to Q2 2024 at the customer's request, meaning that the EMEA region
cannot report any growth. As a result of the reorganization in North
America, unprofitable sales were eliminated, resulting in a decline of -18%
compared to the previous year for the first quarter. The Management Board is
confident that this decline will be made up for over the course of the year
through the continued focused work of the newly established team and new
customers.

In Latin America, investments in aap systems to equip new customers led to a
larger order volume compared with the same quarter of the previous year,
particularly in Brazil and Mexico. These investment orders contributed
significantly to the strong growth in the region. aap is confident that the
investments in aap systems made in Q1 2024 will sustainably strengthen the
business in the region. In the APAC region, existing and new customers also
invested in further aap systems.

The Company is making great progress in the ongoing human clinical trial
with the antibacterial implant technology and has recruited almost 160
patients to date. Due to the continued very positive progress of the study,
there is currently the possibility of significantly reducing the number of
patients to be recruited and completing the recruitment phase as early as
the middle of this year. This would enable an earlier completion of the
follow-up phase and an earlier start to the approval and industrialization
phase. This step will again require substantial funds, which the Company
will raise together with renowned industry partners and private investors.

The German Federal Ministry of Education and Research ("BMBF") is funding
the clinical trial. The grant awarded to the company (funding codes
13GW0313A+B, 13GW0449A+B) is part of the BMBF's "Healthcare industry in the
healthcare research framework program" field of action (= funding body).
According to the BMBF, projects on the topic of "Transferring medical
technology solutions to patient care - proving clinical evidence without
delay" are being funded. For further information, please refer to the
relevant guideline on the BMBF website:
https://www.bmbf.de/foerderungen/bekanntmachung-1376.html.

The Company also made significant progress towards MDR authorization.
Several main product files were submitted to the notified body in the first
few months. aap remains committed to its plan to finalize MDR approval by
the end of 2024. In the financial/legal area, a partial authorization of
shares was completed, a vote without a meeting to lift the lock-up period
for investors was carried out with 100% success and a 10% capital increase
excluding subscription rights was placed at a premium of 37.5%. Due to
personnel bottlenecks in the finance department combined with a new auditing
company, the annual financial statements could not be finalized as planned
and publication had to be postponed.

The second quarter started with a good order basis due to a major order from
an international organization and the postponement of orders placed in Q1
2024. The Management Board therefore remains confident about the Company's
positive development in 2024.




---------------------------------------------------------------------------------------------------

aap Implantate AG (ISIN DE0005066609) - General Standard/Regulated Market -
All German stock exchanges -

About aap Implantate AG

aap Implantate AG is a globally active medical technology company based in
Berlin, Germany. The company develops, produces and markets products for
traumatology. In addition to the innovative LOQTEQ® anatomical plate system,
the IP-protected portfolio includes a wide range of cannulated screws. In
addition, aap Implantate AG has an innovation pipeline with promising
development projects such as antibacterial silver coating technology and
magnesium-based implants. These technologies address critical problems in
traumatology that have not yet been adequately solved. In Germany, aap
Implantate AG sells its products directly to hospitals, purchasing groups
and group clinics, while internationally it primarily uses a broad network
of distributors in around 25 countries. In the United States, the company
relies on a sales strategy via distribution agents through its subsidiary
aap Implants Inc. The aap Implantate AG share is listed in the General
Standard of the Frankfurt Stock Exchange (XETRA: AAQ.DE). For further
information, please visit our website at www.aap.de.

The figures presented in this press release may be subject to technical
rounding differences that do not affect the overall picture.

Forward-looking statements

This release may contain forward-looking statements that are based on the
current expectations, assumptions and forecasts of the Executive Board and
information currently available to it. The forward-looking statements are
not to be understood as guarantees of the future developments and results
mentioned therein. Various known and unknown risks, uncertainties and other
factors could lead to material differences between the actual results,
financial situation, development or performance of the company and the
estimates given here. These factors include those that aap has described in
published reports. Forward-looking statements therefore speak only as of the
date on which they are made. We assume no obligation to update the
forward-looking statements made in this release or to conform them to future
events or developments.


If you have any questions, please contact: aap Implantate AG; Rubino Di
Girolamo, Chairman of the Management Board/ CEO, Lorenzweg 5; 12099 Berlin

Phone: +49 (0)30 75019 - 170; Fax: +49 (0)30 75019 - 290; Email:
r.digirolamo@aap.de


---------------------------------------------------------------------------

22.04.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        aap Implantate AG
                   Lorenzweg 5
                   12099 Berlin
                   Germany
   Phone:          +49 (0) 30 75 019-0
   Fax:            +49 (0) 30 75 019-111
   E-mail:         info@aap.de
   Internet:       www.aap.de
   ISIN:           DE000A3H2101
   WKN:            A3H210
   Listed:         Regulated Market in Frankfurt (General Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1885219

End of News EQS News Service
---------------------------------------------------------------------------

1885219 22.04.2024 CET/CEST